[Hot Topics 2024 and 2025 in dermatology].

Dermatology has made significant advances in recent years. Ruxolitinib cream offers new hope for vitiligo, though reimbursement remains uncertain. A consensus now standardizes the management of Drug Reaction with Eosinophilia and Systemic Symptoms, while IL-26 emerges as a promising target in pustular psoriasis. Concerns about a potential link between dupilumab and cutaneous T-cell lymphoma call for increased clinical vigilance. Meanwhile, bimekizumab marks a breakthrough in hidradenitis suppurativa treatment. Addressing Trichophyton indotineae resistance requires complex strategies. Finally, innovative laser targeting sebaceous glands offers new hope for acne.